

SEP 06 2005

S/N 10/729,276

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Haque et al.	Examiner:	Spivack, P.G.
Serial No.:	10/729,276	Group Art Unit:	1614
Filed:	December 3, 2003	Docket No.:	12695.13USD2
Title:	TREATMENT OF CEREBROVASCULAR DISEASE		

CERTIFICATE UNDER 37 CFR 1.6(d):

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on September 6, 2005.

By: _____

Name: _____

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it was originally submitted on March 3, 2004 prior to the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

Since this application was filed after June 30, 2003, a copy the U.S. Patent listed on the enclosed Form 1449 is not provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked

BEST AVAILABLE COPY


as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: September 6, 2005



Brian R. Dorn
Reg. No. 57,395
BRD/mls



Date Mailed: September 6, 2005

Sheet 1 of 1

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: HAQUE ET AL.	
	Filing Date: 12/03/2003	Group Art Unit: 1614

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,339,085	01/15/2002	Haque			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Sheet 1 of 6

Date Mailed: June 14, 2001

FORM 1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12595.13USU1	Application Number: 09/820,199
	Applicant: HAQUE ET AL.	
	Filing Date: 03/28/2001	Group Art Unit: 1614

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
2/2	3,206,463	09/14/1965	Bectz			
	3,910,921	10/07/1975	Esanu			
	3,987,177	10/19/1976	Giudicelli et al.			
	4,032,534	06/28/1977	Chodkiewicz			
	4,036,844	07/19/1977	Thorne et al.			
	4,053,607	10/11/1977	Thorne et al.			
	4,137,316	01/30/1979	Esanu			
	4,167,562	09/11/1979	Evans			
	4,361,570	11/30/1983	Fid			
	4,369,172	01/18/1983	Scher et al.			
	4,374,841	02/22/1983	Descamps et al.			
	4,515,771	05/07/1985	Fino			
	4,567,179	01/28/1986	Lombardino			
	4,569,938	02/11/1986	Esanu			
	4,569,939	02/11/1986	Esanu			
	4,581,363	04/08/1986	Esanu			
	4,605,741	08/12/1986	Zagnoli et al.			
	4,730,042	03/08/1988	Hoge et al.			
	4,735,950	04/05/1988	Esanu			
	4,735,956	05/05/1988	Baldwin et al.			
	4,837,239	06/06/1989	Benjamin et al.			
	4,843,071	06/27/1989	Hohenwarter			
	4,962,121	10/09/1990	Hamburger et al.			
	5,001,115	03/19/1991	Sloan			
	5,053,396	10/01/1991	Blass			
	5,118,505	06/02/1992	Kellinger			
	5,130,324	07/14/1992	Ulrich et al.			
	5,132,115	07/21/1992	Walter et al.			

EXAMINER WILLIAM R. A. JARVIS PRIMARY EXAMINER	DATE CONSIDERED 5/13/02
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

Sheet 2 of 6

Date Mailed: June 14, 2001

FORM 1449

INFORMATION DISCLOSURE STATEMENT

OIP
JUN 22 2001
PATENT & TRADEMARK
OFFICE

IN AN APPLICATION

(See several sheets if necessary)

Docket Number:

12695.15USU1

Application Number:

09/820,199

Applicant: HAQUE ET AL.

Filing Date: 03/28/2001

Group Art Unit: 1614

5,210,083	05/11/1993	Pfaffman					
5,213,813	05/25/1993	Kornacki et al.					
5,254,597	10/19/1993	Bucklin et al.					
5,254,573	10/19/1993	Sarfontein					
5,272,165	12/21/1993	Ulrich et al.					
5,278,154	01/11/1994	Lacoste et al.					
5,288,716	02/22/1994	Spock					
5,326,757	07/05/1994	Demopoulos					
5,328,453	07/12/1994	Sibalis					
5,372,999	12/13/1994	Schneider et al.					
5,385,937	01/31/1995	Stamler et al.					
5,420,112	05/30/1995	Lewis et al.					
5,441,972	08/15/1995	Ogata et al.					
5,504,090	04/02/1996	Neely					
5,563,126	10/08/1996	Allen et al.					
5,569,459	10/29/1996	Shlyankevich					
5,569,648	10/29/1996	Lewis et al.					
5,631,271	05/20/1997	Sarfontein					
5,633,228	05/27/1997	Lewis et al.					
5,648,335	07/15/1997	Lewis et al.					
5,728,684	03/17/1998	Chong et al.					
5,733,884	03/31/1998	Burkul et al.					
5,733,916	03/31/1998	Neely					
5,770,215	06/23/1998	Moshyell					
5,795,873	08/18/1998	Allen					
5,804,163	09/08/1998	Gibby et al.					
5,804,594	09/08/1998	Murad					
5,833,998	11/10/1998	Biedermann et al.					
5,834,446	11/10/1998	Dow et al.					
5,840,683	11/24/1998	Fujii et al.					
5,847,008	12/08/1998	Doabber et al.					

EXAMINER

WILLIAM R. A. JARVIS

DATE CONSIDERED

5/13/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

Date Mailed: June 14, 2001

Sheet 3 of 6

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION <small>(File several sheets if necessary)</small>	Docket Number: 12695.13USU1	Application Number: 09/820.199
	Applicant: HAQUE ET AL.	
	Filing Date: 03/28/2001	Group Art Unit: 1614

5,858,017	01/12/1999	Demopoulos et al.				
5,859,031	01/12/1999	Adams et al.				
5,874,420	02/23/1999	Pelleg				
5,874,443	02/23/1999	Klely et al.				
5,888,514	03/30/1999	Welsman				
5,944,020	08/31/1999	Markov et al.				
6,043,299	03/28/2000	Dballin et al.				

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YRS	NO
	431,350	01/14/1976	BE				X
	863,754	05/29/1976	BE				X
	361 183	04/30/1975	CH				X
	1 958 226	05/27/1970	DE				X
	37 05 549 A1	09/01/1988	DE				X
	43 44 751 A1	06/20/1995	DE				X
	24 61 742 A	07/08/1976	DT				X
	0 121 036 A1	10/10/1984	EP				
	0 144 051 A2	06/12/1985	EP				
	0 270 026 A2	06/08/1988	EP				
	0 416 248 A2	03/13/1991	EP				
	0 891 719 A1	01/20/1999	EP				
	846,376	03/26/1941	FR				X
	1,323,941	12/15/1963	FR				X
	5,352 M	12/26/1967	FR				X
	6,453 M	12/16/1968	FR				X
	1,579,544	08/29/1969	FR				X
	2,101,010	03/31/1972	FR				X
	2,255,883	07/25/1975	FR				X
	2,428,640	01/11/1980	FR				X

EXAMINER WILLIAM R. A. JARVIS PRIMARY EXAMINER	DATE CONSIDERED 5/13/02
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

Sheet 4 of 6

Date Mailed: June 14, 2001

FORM 1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (attach several sheets if necessary)	Decklet Number: 12695.13USUI	Application Number: 09/820,199
	Applicant: HAQUE ET AL.	
	Filing Date: 03/28/2001	Group Art Unit: 1614

013 939	12/22/1965	GB							
1,172,800	12/03/1969	GB							
1 201 014	08/05/1970	GB							
1 297 080	11/22/1972	GB							
1 360 536	07/17/1974	GB							
1 493 993	12/07/1977	GB							
2 254 556 A	10/14/1992	GB							
5,801 M	03/28/1968	FR							X
2 034 539	12/11/1970	FR							X
45-21959	07/02/1973	JP							X
54-17130	02/08/1979	JP							X
WO 83/00085	01/20/1983	PCT							
WO 91/19500	12/28/1991	PCT						Abstract	
WO 94/18965	09/01/1994	PCT							
WO 99/03365	01/28/1999	PCT							
WO 99/53928	10/28/1999	PCT							

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

250	Aybak, M. et al., "Effect of Oral Pyridoxine Hydrochloride Supplementation on Arterial Blood Pressure in Patients with Essential Hypertension". <i>Drug Res.</i> , Vol. 45, No. 12, pp. 1271-1273 (1995).
	"B Vitamins May Cut Heart Disease Risk", <i>Harvard Health Letter</i> , 1 page (1998)
	Baliga, R. et al., "Hyperhomocysteinemia in Type 2 Diabetes Mellitus: Cardiovascular Risk Factors and Effect of Treatment with Folate Acid and Pyridoxine", <i>Endocrine Practices</i> , Vol. 6, No. 6, pp. 435-441 (November/December 2000).
	Bivica, S., "Homocysteine: A Cardiovascular Risk Factor Worth Considering", http://www.quickwatch.com/03HealthPromotion/homocysteine.html , 2 pages (©1997)
	Bornstein, A., "Vitamin B6 in Clinical Neurology", <i>Annals of New York Academy of Sciences</i> , Vol. 585, pp. 250-260 (1990)
	Borger, A.R. et al., "Dose response, constancy, and differential fiber vulnerability in human toxic neuropathy: A prospective study of pyridoxine neurotoxicity", <i>Neurology</i> , Vol. 42, No. 7, pp. 1367-1370 (July 1992)
	Bhagavan, H. et al., "Effect of Postweaning Pyridoxine Deficiency on Growth and Concentration of the Coenzyme Pyridoxal-5-phosphate in Heart, Kidneys, Lungs, and Adrenals in Rats", <i>Pediat. Res.</i> , Vol. 10, pp. 730-732 (1976).
	Dode, W. et al., "Pyridoxal-5-Phosphate and Pyridoxal Biokinetics in Male Wistar Rats Fed Graded Levels of Vitamin B-6", <i>J. Nutr.</i> , Vol. 121, No. 11, pp. 1738-1745 (November 1991)
	Chasan-Taber, L. et al., "A Prospective Study of Folate and Vitamin B6 and Risk of Myocardial Infarction in US Physicians", <i>Journal of the American College of Nutrition</i> , Vol. 15, No. 2, pp. 136-143 (April 1996)

EXAMINER	WILLIAM R. A. JARVIS	DATE CONSIDERED	5/13/02
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not in conformance of this form for next communication to the Applicant.			

06/10/02 12:00 FAX 813 236 2485

RIDOUT & MAYBEE

014

Sheet 5 of 6

Date Mailed: June 14 2001

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

12695.13USU1

Application Number:

09/820,199

Applicant: HAQUE ET AL.

Filing Date: 03/28/2001

Group Art Unit: 1614

- Cho, Y. et al., "In Vivo Evidence for a Vitamin B-6 Requirement in Carnitine Synthesis", *J. Nutr.*, Vol. 120, pp. 258-265 (1990)
- "Computer Generated Search Reports", 70 pages (May 1999)
- Ellis, J. et al., "Prevention of Myocardial Infarction by Vitamin B6", *Res. Commun. Molec. Pathol. Pharmacol.*, Vol. 89, No. 2, pp. 208-220 (August 1995)
- Folsom, A. et al., "Clinical Investigation and Reports: Prospective Study of Coronary Heart Disease Incidence in Relation to Fasting Total Homocysteine, Related Genetic Polymorphisms, and B Vitamins: The Atherosclerosis Risk in Communities (ARIC) Study", *Circulation*, Vol. 98, pp. 204-210 (July 21, 1998).
- Harada, K. et al., "Studies on Vitamin B6. (IV) Behavior of Pyridoxal Acylates in the Body After Parenteral Administration", *Vitamin Journal of the Vitamin Society of Japan*, Vol. 45, No. 2, pp. 69-75 (February 1972)
- Haddock, J., "Vitamins and minerals: efficacy and safety", *Am J Clin Nutr*, Vol. 66, pp. 421 - 437 (1997)
- Hoover, D.M. et al., "Ultrastructural Lesions of Pyridoxine Toxicity in Beagle Dogs", *Vet. Pathol.*, Vol. 18, pp. 769-777 (1981)
- Kok, F. et al., "Low Vitamin B6 Status in Patients with Acute Myocardial Infarction", *Am. J. Cardiol.*, Vol. 63, pp. 513-516 (March 1, 1989)
- Korynyk et al. Schiff Bases of Pyridoxal: Their Structure and the Stabilization of their Ring-Chain Tautomeric Forms by Acylation, *Tetrahedron*, 26 (23), 5415-25, 1982.
- Krinka, G. et al., "Pyridoxine Megavitaminosis: An Analysis of the Early Changes Induced with Massive Doses of Vitamin B6 in Rat Primary Sensory Neurons", *J. Neuropathol. Exp. Neurol.*, Vol. 44, No. 7, pp. 117-129 (March 1985)
- Kubyshkin, V. et al., "Comparative characteristics of the arrhythmic syndrome and the possibility for its coenzyme correction in dilated and hypertrophic cardiomyopathy", *Abstracts*, 1 pg. (1989).
- Lai, K. et al., "Hypertensive action of 5-HT receptor agonists in the vitamin B6-deficient hypertensive rat", *Eur. J. Pharmacol.*, Vol. 234, Nos. 2/3, pp. 183-189 (April 1993)
- Lai, K. et al., "Calcium channels in vitamin B6 deficiency-induced hypertension", *Journal of Hypertension*, Vol. 11, No. 12, pp. 1357-1362 (December 1993)
- Lai, K. et al., "The effect of vitamin B6 on the systolic blood pressure of rats in various animal models of hypertension", *Journal of Hypertension*, Vol. 14, No. 3, pp. 353-363 (March 1996)
- Levy, H. et al., "Pyridoxine Deficiency in Congestive Heart Failure", *P.S.S.B.M.*, Vol. 101, pp. 617-621 (1959)
- Masaro, M. et al., "Changes in Plasma Pyridoxal Phosphate (PLP) in Diabetic (D), Hypertensive (HTN) and Hypertensive-diabetic (HTN-D) Men Fed A Constant Vitamin B-6 (B6) Diet", *Source Unknown*, pp. 1254 (1990).
- Markov, A. et al., "Hemodynamic, electrocardiographic, and metabolic effects of fructose diphosphate on acute myocardial ischemia", *American Heart Journal*, Vol. 100, No. 5, pp. 639 - 646 (November 1980)
- Mendelsohn, A. et al., "Hemodynamic and Clinical Effects of Oral Levodopa in Children With Congestive Heart Failure", *JACC*, Vol. 30, No. 1, pp. 237-242 (July 1997).
- Merrill, Jr. et al. A. et al., "Diseases associated with defects in vitamin B6 metabolism or utilization", *Ann. Rev. Nutr.*, Vol. 7, pp. 137-156 (1987)
- Mulveney, D. et al., "Electrocardiographic changes in vitamin B6 deficient rats", *Cardiovascular Research*, Vol. 13, pp. 506-513 (1979).
- Omenn, G. et al., "Preventing Coronary Heart Disease", *Circulation*, Vol. 97, pp. 421-424 (1998)
- Paulose, C. et al., "Sympathetic Stimulation and Hypertension in the Pyridoxine-Deficient Adult Rat", *Hypertension*, Vol. 11, No. 4, pp. 387-391 (April 1988)

EXAMINER

WILLIAM R. A. JARVIS

DATE CONSIDERED

5/13/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

06/10/02 12:01 FAX 613 236 2485

RIDOUT & MAYBEE

Sheet 6 of 6

Date Mailed: June 14, 2001

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12695.13USU1	Application Number: 09/820,199
	Applicant: HAQUE ET AL.	
	Filing Date: 03/28/2001	Group Art Unit: 1614

		Rao, R. et al., "Failure of Pyridoxine to Improve Glucose Tolerance in Diabetics", <i>Journal of Clinical Endocrinology & Metabolism</i> , Vol. 50, No. 1, pp. 198-200 (January 1980).
		Rimm, E. et al., "Folate and Vitamin B6 From Diet and Supplements in Relation to Risk of Coronary Heart Disease Among Women", <i>JAMA</i> , Vol. 279, No. 5, pp. 359-364 (February 4, 1998)
		Sakumagi, T. et al., "The Synthesis of Long Chain Fatty Acid Derivatives of the Vitamin B6 Group", <i>J. Am. Chem. Soc.</i> , Vol. 78, pp. 839-842 (February 20, 1956)
		Schulz, R. et al., "Differential changes in left and right ventricular adenylyl cyclase activities in congestive heart failure", <i>The American Physiological Society</i> , Vol. 272, No. 2, Part 2 of Two Parts, pp. H884 - H893 (February 1997)
		Solhi, R. et al., "Inotropic Responses to Isoproterenol in Congestive Heart Failure Subsequent to Myocardial Infarction in Rats", <i>Journal of Cardiac Failure</i> , Vol. 1, No. 5, pp. 391 - 399 (December 1995)
		Takuma, Y. et al., "Combination Therapy of Infantile Spasms With High-Dose Pyridoxal Phosphate and Low-Dose Carbamazepine", <i>Journal of Child Neurology</i> , Vol. 11, No. 1, pp. 35-40 (January 1996)
		Tanaka, T. et al., "Pyridoxine Derivatives", <i>Chemical Abstracts</i> , Vol. 62, No. 12, 1 page (June 7, 1965)
		Trozhko, D. et al., "P2 purinoceptor antagonist properties of pyridoxal-S-phosphate", <i>Eur. J. Pharmacol.</i> , Vol. 259, No. 3, pp. 295-300 (July 11, 1994)
		Vanderjeer, D. et al., "Vitamin B6 Status in a Healthy Elderly Population", <i>Annals New York Academy of Sciences</i> , pp. 362 - 364 (1990)
		Verhoef, P. et al., "A Common Mutation in the Methylene-tetrahydrofolate Reductase Gene and Risk of Coronary Heart Disease: Results Among U.S. Men", <i>JACC</i> , Vol. 32, No. 2, pp. 353 - 359 (August 1998)
		Verhoef, P. et al., "Homocysteine Metabolism and Risk of Myocardial Infarction: Relation with Vitamins B6, B12, and Folate", <i>Am. J. Epidemiol.</i> , Vol. 143, No. 9, pp. 843-859 (May 1, 1996)
		Vennart, W.J.H. et al., "Vitamin B6 and coronary artery disease. Epidemiological observations and case studies", <i>Atherosclerosis</i> , Vol. 63, pp. 235-238 (February 1987)
		Vidrio, H., "Interaction with Pyridoxal as a Possible Mechanism of Hydralazine Hypotension", <i>Journal of Cardiovascular Pharmacology</i> , Vol. 15, pp. 150-156 (1990)
		Viscontini, V. et al., "Oberstrinige Derivate des Pyridoxals", <i>Helvetica Chimica Acta</i> , Vol. 34, No. 296, pp. 2438-2439 (1951)
		Windbank, A., "Neurotoxicity of Pyridoxine Analogs is Related to Coenzyme Structure", <i>Neurochemical Pathology</i> , Vol. 9, pp. 159-167 (1985)
		Yam, A. et al., "Effect of vitamin B6 on lenses of diabetic rats", <i>Indian Journal of Experimental Biology</i> , Vol. 36, pp. 1269-1272 (December 1998)
		Zamploni, J. et al., "The utilization of intravenously infused pyridoxine in humans", <i>Clinica Chimica Acta</i> , Vol. 229, Nos. 1, 2, pp. 27-36 (September 1994)

EXAMINER

WILLIAM R. A. JARVIS
PRIMARY EXAMINER

DATE CONSIDERED

5/13/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not in conformance to the Applicant.

06/10/02 12:01 FAX 613 236 2485

RIDOUT & MAYBEE

016

006

RIDOUT&MAYBEE

PAGE 1 of 2

Form PTO-1449
(Rev. 9-94)U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
29399-0014SERIAL NO.
US 09/820,199

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

APPLICANT
Medicare International Inc.FILING DATE
3/28/2001GROUP
1614

(Use several sheets if necessary)

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

Volpe J. J., "Management of Neonatal Seizures", *Critical Care Medicine*, Vol. 3, No. 1, pp. 43 to 46 (1977 Jan-Feb)Broff H. et al., "New Aspects to the Treatment of Cerebral Ischemia", *Miner Medica/Intake Wachensdorf*, Vol. 125, No. 45, pp. 646 to 650 (1975)

WILLIAM R. A. JARVIS

DATE CONSIDERED

5/16/02

06/10/02 12:01 FAX 613 236 2485

RIDOUT & MAYBEE

017

004

05/17/02 11:53 FAX 613 236 2485

RIDOUT&MAYBEE

PAGE 1 of 1

Form PTO-1449
(Rev. 9-94)U.S. Department of Commerce
Patent and Trademark Office

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.
29399-0014SERIAL NO.
US 09/820,199APPLICANT
Medicare International Inc.FILING DATE
8/28/2001GROUP
1614

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>WJ</i>	6210,095	October 30, 2001	Newcomb			August 27, 1998

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER INFORMATION (including author, title, date, pertinent pages, etc.)

EXAMINER

WILLIAM R. A. JARVIS

DATE CONSIDERED

5/17/02

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.